摘要
目的:观察辅酶Q10联合瑞舒伐他汀治疗冠心病早期心功能减退患者的效果。方法:回顾性分析2017年3月至2020年4月该院收治的94例冠心病早期心功能减退患者的临床资料,按照治疗方案不同分为对照组(n=47)和观察组(n=47)。两组患者均给予常规治疗,在此基础上对照组采用瑞舒伐他汀钙片治疗,观察组在对照组基础上采用辅酶Q10胶囊治疗。比较两组临床疗效、治疗前后心功能指标[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、心脏指数(CI)]水平、血清学指标[肥胖抑制素(obestatin)、正五聚蛋白3(PTX3)]水平,以及不良反应发生率。结果:观察组治疗总有效率为95.74%(45/47),高于对照组的76.60%(36/47),差异有统计学意义(P<0.05);治疗后,两组LVEF、CI水平均高于治疗前,且观察组高于对照组;两组LVESD水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组obestatin、PTX3水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:辅酶Q10联合瑞舒伐他汀治疗冠心病早期心功能减退患者可提高治疗总有效率,改善心功能指标水平,以及降低血清学指标水平,效果优于单纯瑞舒伐他汀治疗。
Objective: To observe effects of Coenzyme Q10 combined with Rosuvastatin in treatment of patients with coronary heart disease and early cardiac function decline. Methods: The clinical data of 94 patients with coronary heart disease and early cardiac function decline who were admitted to our hospital from March 2017 to April 2020 were retrospectively analyzed. According to different treatment plans, they were divided into control group(n=47) and observation group(n=47). Both groups were given conventional treatment. On this basis, the control group was treated with Rosuvastatin calcium tablets, while the observation group was treated with Coenzyme Q10 capsules on the basis of that of the control group. The clinical efficacy, the cardiac function index levels [left ventricular ejection fraction(LVEF), left ventricular end-systolic diameter(LVESD), cardiac index(CI)], the serological index levels [obestatin, pentraxin 3(PTX3)], and the incidence of adverse reactions were compared between the two groups before and after the treatment. Results: The total effective rate of the observation group was 95.74%(45/47), which was higher than 76.60%(36/47) of the control group, and the difference was statistically significant(P<0.05). After the treatment, the levels of LVEF and CI in the two groups were higher than before the treatment, and those of the observation group were higher than those of the control group;the LVESD levels in the two groups were lower than before the treatment, and that of the observation group was lower than that of the control group;and the differences were statistically significant(P<0.05). After the treatment, the levels of obestatin and PTX3 in the two groups were lower than those before the treatment, those of the observation group were lower than those of the control group, and the differences were statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Coenzyme Q10 combined with Rosuvastat
作者
呼风
HU Feng(Department of Cardiology of Jinzhou Second Hospital,Jinzhou 121000 Liaoning,China)
出处
《中国民康医学》
2022年第13期17-19,共3页
Medical Journal of Chinese People’s Health
